乌蔹莓灌肠对远端溃疡性结肠炎患者的临床疗效

Clinical effects of enema of Cayratia japonica on patients with distal ulcerative colitis

目的探讨乌蔹莓灌肠对远端溃疡性结肠炎患者的临床疗效。方法60例患者随机分为对照组和观察组,每组30例,对照组给予美沙拉嗪肠溶片,观察组在对照组基础上加用乌蔹莓灌肠,疗程8周。检测临床疗效、生活质量评分、DAI评分、Mayo活动指数、肠黏膜屏障功能指标(DAO、ET、D-乳酸)、肠道菌群(双歧杆菌、乳酸杆菌、大肠杆菌、肠球菌)、炎症因子(IL-10、IL-6、TNF-α)、安全性指标变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,观察组生活质量评分、IL-10升高(P<0.05),DAI评分、Mayo活动指数、肠黏膜屏障功能指标、IL-6、TNF-α降低(P<0.05),双歧杆菌、乳酸杆菌增加(P<0.05),大肠杆菌、肠球菌减少(P<0.05),并比对照组更明显(肠球菌除外)(P<0.05)。2组未发现不良反应。结论乌蔹莓灌肠可安全有效地改善远端溃疡性结肠炎患者DAI评分和Mayo活动指数,其机制可能与调节菌群稳态、修复肠黏膜屏障、抑制炎症因子释放有关。

AIM To explore the clinical effects of enema of Cayratia japonica(Thunb.)Gagnep.on patients with distal ulcerative colitis.METHODS Sixty patients were randomly assigned into control group(30 cases)for 8-week intervention of Mesalazin Enteric-coated Tablets,and observation group(30 cases)for 8-week intervention of both enema of C.japonica and Mesalazin Enteric-coated Tablets.The changes in clinical effects,life quality scores,DAI score,Mayo activity index,intestinal mucosal barrier function indices(DAO,ET,D-lactic acid),intestinal flora(Bifidobacterium,Lactobacillus,Escherichia coli,Enterococcus),inflammatory factors(IL-10,IL-6,TNF-α)and safety indices were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05).After the treatment,the observation group displayed increased life quality scores,IL-10(P<0.05),decreased DAI score,Mayo activity index,intestinal mucosal barrier function indices,IL-6,TNF-α(P<0.05),enhanced Bifidobacterium,Lactobacillus(P<0.05),and reduced Escherichia coli,Enterococcus(P<0.05),which were more obvious than those in the control group(except for Enterococcus)(P<0.05).No obvious adverse reactions were observable in the two groups.CONCLUSION For the patients with distal ulcerative colitis,enema of C.japonica can safely and effectively improve DAI score and Mayo activity index,which may contribute to the regulation of bacterial homeostasis,repairment of intestinal mucosal barrier and inhibition of inflammatory factor release.